GlassScriptPhysician profile
Michael Q Coggin
NPI 1942602008
$6,668.56
in general payments reported to CMS, 2019-2025
36 companies · $1,126 in 2025
The $1,126 reported for 2025 was more than what 89% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,289 · 2022: $1,376 · 2023: $1,492 · 2024: $1,385 · 2025: $1,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,003.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,651.75 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $911.89 | 2021-2025 | |
| Amgen INC. | $672.62 | 2021-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $639.10 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $517.57 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Esperion Therapeutics, INC. | $383.72 | 2021-2025 | Nexletol |
| Pfizer INC. | $258.03 | 2022-2025 | |
| Glaxosmithkline, LLC. | $212.90 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $147.27 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $123.72 | 2021-2024 | |
| Abbott Laboratories | $113.86 | 2021-2024 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $100.67 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.30 | 2021-2025 | Jardiance, Tradjenta |
| Biohaven Pharmaceutical Holding Company LTD. | $86.85 | 2022 | |
| Boston Scientific Corporation | $86.62 | 2023-2025 | Watchman Access System |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $74.49 | 2022-2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $65.61 | 2021-2022 | |
| Philips North America LLC | $56.90 | 2024 | (Ck6) Holter |
| Biohaven Pharmaceuticals, INC. | $46.68 | 2021 | |
| Dexcom, INC. | $44.94 | 2024-2025 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $43.28 | 2023 | Krystexxa |
| Exact Sciences Corporation | $39.46 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $34.51 | 2024-2025 | Trintellix |
| Sanofi-Aventis U.S. LLC | $34.11 | 2022 | |
| Atricure, INC. | $25.57 | 2022 | |
| Clarus Therapeutics INC. | $24.50 | 2021 | |
| Organon LLC | $22.88 | 2022 | |
| Antares Pharma, INC. | $20.06 | 2025 | Xyosted |
| Collegium Pharmaceutical, INC. | $19.42 | 2025 | Jornay Pm |
| Baxter Healthcare | $18.23 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Watermark Medical, INC. | $18.12 | 2024 | |
| Genentech USA, INC. | $16.00 | 2021 | |
| Seqirus USA INC | $15.57 | 2024 | Flucelvax, Fluad |
| Amneal Pharmaceuticals LLC | $15.37 | 2024 | Unithroid |
| Merck Sharp & Dohme LLC | $14.90 | 2021 | |
| Augmedics INC. | $12.09 | 2023 | Xvision |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Coggin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.